Lumexa Imaging Earnings Call Highlights Growth Momentum

Lumexa Imaging Holdings, Inc. ((LMRI)) has held its Q4 earnings call. Read on for the main highlights of the call.

Lumexa Imaging Holdings, Inc. struck an upbeat tone on its latest earnings call, emphasizing broad-based growth, improving margins and a significantly stronger balance sheet after its IPO. Management acknowledged some near-term noise from one-time costs and Q1 volume timing, but reiterated confidence in the long-term plan and kept guidance intact, signaling a constructive outlook for investors.

Steady Revenue Growth Caps Solid Year

Lumexa reported consolidated Q4 2025 revenue of $267.7 million, up 7.9% from a year earlier, capping a full-year total of $1.023 billion, up 7.8% versus 2024. Management framed the growth as healthy and diversified, with both same-center performance and new site additions contributing, reinforcing the company’s positioning in outpatient imaging.

EBITDA Strength and Margin Expansion Impress

Adjusted EBITDA jumped 18.6% year over year in Q4 to $63.8 million, lifting margin to 23.8%, a 150-basis-point improvement. For 2025, adjusted EBITDA reached $230.2 million with a 22.5% margin, up 14.6%, underscoring operating leverage as volumes grow and efficiency initiatives begin to scale.

Advanced Imaging Volumes Drive Higher-Acuity Mix

The company completed 1.4 million advanced imaging exams system-wide in Q4, up 7.7%, with same-center advanced imaging growth around 8% and consolidated growth about 7.1%. PET scans rose in the mid-teens for the year, shifting the mix toward higher-acuity modalities and supporting stronger rates and revenue per exam.

IPO Proceeds Transform Balance Sheet

Lumexa used $406 million of net IPO proceeds to pay down debt, cutting leverage by roughly two turns to 3.5x by December and improving cash on hand to $58.8 million from $26.1 million at the end of 2024. Credit ratings were upgraded to B+ at S&P and B2 at Moody’s, and management expects more than $50 million in annual interest cash savings.

Record De Novo Openings Support Growth Runway

The company opened a record nine de novo centers in 2025, highlighting a robust development pipeline and confidence in local demand. Management plans to open eight to ten de novo locations annually, noting that new centers typically reach breakeven in about a year and that openings will likely be weighted to the second half of each year.

Technology Investments Boost Throughput and Efficiency

Lumexa’s FastScan platform increased scheduling throughput by nearly 40% in centers where it is deployed, with adoption at about 50% of the fleet by year-end 2025 and a target of roughly two-thirds by the end of 2026. The company is also rolling out virtual cockpit technology to reduce downtime and flex staffing, while a partnership with Ferrum Health aims to accelerate the use of FDA-cleared AI tools.

Strategic Deals and Partnerships Expand Network Reach

A new joint venture with the University of Pittsburgh Medical Center extends Lumexa’s footprint to 14 states and deepens its hospital relationships. The company also completed a tuck-in acquisition in North Carolina and secured a return-to-network agreement with a major payer in New Jersey, which materially supported Q4 revenue.

Patient Loyalty Underpins Stable Demand

Patient satisfaction remains a key asset, with Net Promoter Scores consistently above 90, suggesting strong loyalty and word-of-mouth referral potential. In mammography, about 85% of screening volume comes from returning patients, and management highlighted successful efforts to boost annual compliance in this recurring, preventive-care segment.

GAAP Loss Reflects One-Time Transaction Costs

Despite strong operating metrics, Lumexa reported a GAAP net loss of $28.7 million in Q4, slightly wider than the $25.1 million loss a year earlier. Management attributed the deficit largely to refinancing and IPO-related transaction costs, framing the charges as non-recurring and separate from the company’s underlying earnings power.

Q1 Volume Timing and Weather Create Near-Term Drag

The company expects Q1 2026 adjusted EBITDA to be roughly flat year over year as some January volumes were pulled into December and storms in New Jersey, Texas and several Southern states disrupted activity. While a portion of the lost exams has already been recovered, management does not expect a full rebound in the quarter, tempering near-term momentum.

Capex Intensity Clouds Near-Term Modeling

Lumexa continues to invest heavily in new centers and equipment refreshes, with system-wide capital spending historically above $100 million annually. However, the company did not provide specific 2026 CapEx guidance, leaving some uncertainty for investors and analysts trying to model free cash flow and the pace of reinvestment.

Stock-Based Compensation Remains a Non-Cash Headwind

Stock-based compensation currently includes acquisition-related awards that will be fully amortized by the end of 2026, easing some future expense pressure. Still, the company expects ongoing equity grants to employees and management to continue beyond 2026, representing a recurring non-cash drag on reported earnings metrics.

Revenue Mix Complicated by Pass-Through Items

Management and other revenues include $57.2 million of management fees and pass-through items that inflate the top line without contributing meaningfully to margin. Because pass-through revenue has limited impact on EBITDA, the company cautioned that investors should focus on underlying operating trends rather than headline revenue alone when modeling profitability.

Guidance Reinforces Confidence in 2026 Trajectory

Lumexa reaffirmed its 2026 revenue outlook of $1.045 billion to $1.097 billion and adjusted EBITDA of $234 million to $242 million, which includes about $7 million in public-company costs and implies roughly 7% EBITDA growth excluding those costs. The company introduced adjusted EPS guidance of $0.71 to $0.77 and expects volumes to keep rising, led by advanced modalities, while opening 8 to 10 de novo sites annually and targeting leverage below 3x over time.

Lumexa’s call painted a picture of a company leaning into growth while steadily de-risking its balance sheet, even as short-term noise from timing shifts, weather and non-cash items weighs on reported earnings. For investors, the story hinges on continued strength in advanced imaging, successful execution on de novo and technology plans, and disciplined capital deployment to convert growth into durable shareholder returns.